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Significance of epidermal growth factor receptor and c-erbB-2 protein
expression in transitional cell cancer of the upper urinary tract for
tumour recurrence at the urinary bladder
T Imai, M Kimura, M Takeda and Y Tomita
Department of Urologv, Niigata University School ofMedicine, Asahimachi 1, Niigata 951, Japan.
Summary An immunohistochemical study of the expression of epidermal growth factor receptor (EGFR) and
c-erbB-2 protein was performed in fresh-frozen sections from 30 patients with transitional cell cancers (TCCs)
of the upper urinary tract (15 renal pelvic cancers, 15 ureteral cancers) who underwent total nephroureterec-
tomy. We followed them and examined whether TCC appeared in the urinary bladder. The follow-up period
ranged from 116 to 2348 days (mean 666 days). The mean period until a secondary urinary bladder cancer
appeared was 306 days (116-829 days). Thirteen of those 30 TCCs (43.3%) showed increased expression of
EGFR, and 11 TCCs (36.7%) showed increased expression of c-erbB-2. In 12 of 30 patients (40.00 0), a
secondary urinary bladder cancer appeared after surgery. In only one of the ten patients (10.0%) whose
tumours did not exhibit increased expression of either of these receptors the tumour recurred in bladder. On
the other hand, in 11 of 20 (55.0%) patients whose tumours had increased EGFR and,or c-erbB-2 expression,
secondary urinary bladder cancers recurred after surgery (P<0.05). Thus, the recurrence rate of TCCs with
increased EGFR and/or c-erb-2 expression was significantly higher than that of tumours showing no
increased expression of these receptors (P<0.01). These results suggest that the immunohistochemical
detection of the expression of EGFR and c-erbB-2 in urothelial cancers of the upper urinary tract might be a
useful method for determining the likelihood of secondary bladder cancer recurrences.
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Epidermal growth factor receptor (EGFR) is a transmemb-
rane glycoprotein which has tyrosine kinase activity and
augments cell proliferation on interaction with its ligand,
EGF. EGFR is expressed at increased levels in certain car-
cinomas, such as breast cancer (Sainsbury et al.. 1987; Harris
et al.. 1989), oesophageal cancer (Ozawa et al., 1989) and
urinary bladder cancer (Neal et al., 1985. 1990; Lipponen
and Eskelinen. 1994). In those carcinomas, the expression of
the EGFR appears to be associated with the patient's prog-
nosis. The c-erbB-2 gene encodes a transmembrane glycop-
rotein which is supposed to have similar function to EGFR
(Yamamoto et al.. 1986: Lee et al.. 1989). Immunohis-
tological studies have revealed that the c-erbB-2 protein is
commonly located in fetal epithelial cells but is barely detec-
table in post-natal tissues (Mori et al., 1989). Therefore, this
protein has been assumed to be a growth factor receptor that
plays a role in mitogenic signalling in the fetal epithelium.
The overexpression of c-erbB-2 has been shown to be cor-
related with lymph node metastasis and a poorer prognosis
in those with breast cancer, suggesting that c-erbB-2 may
play an important role in the progression of cancers (Slamon
et al., 1987; Walker et al.. 1989).
Transitional cell cancers (TCCs) in the urinary tract appear
to occur multicentrically. After a total nephroureterectomy
for TCCs of the renal pelvis or ureter, patients require con-
tinued surveillance, because the incidence of a subsequent
bladder cancer is about 20-40% (Batara and Grabsteld,
1976; Kakizoe et al., 1980; Nielsen and Ostri, 1988; Catalona,
1992). Although several studies have been performed to
determine the relationship between urothelial cancers of the
upper urinary tract and secondary urinary bladder cancers
after total nephroureterectomy, none of the criteria examined
was found to be predictive of recurrence in urinary bladder.
We reported that EGFR and c-erbB-2 were also overexp-
ressed in TCCs in ureter or renal pelvis, and that the degree
of expression was correlated with the histopathological grade
of the tumour and the degree of invasion (Kimura et al.,
1992). In this study. our interest was focused on correlation
between the degree of expression of EGFR or c-erbB-2 and
recurrence in the urinary bladder after surgical removal of
TCCs in ureter or renal pelvis. Our data show that recur-
rence in the bladder occurs more frequently in patients with
EGFR- and/or c-erbB-2-overexpressing TCCs of the upper
urinary tract.
Materials and methods
Patients
Thirty patients (24 males and six females; mean age 67.9
years, range 53-81) who had undergone total nephroure-
retectomy for renal pelvic (15 cases) or ureteral cancer (15
cases) were admitted to this study. All the tumours were
diagnosed pathologically as TCC. The patients were not
treated with either chemotherapy or radiotherapy before
surgery. Patients with bladder cancer or distant metastasis
before surgery or with lymph node metastasis identified by
histopathology after surgery were excluded from this study.
Seven patients had no invasion of the lamina propria (pTa),
eight showed lamina propria invasion (pTl), seven had
invasion of superficial muscle (pT2) and eight had invasion
of the deep muscle (pT3). Pathological grade 1 tumours (high
differentiation) occurred in five patients, grade 2 (moderate
differentiation) in 20 and grade 3 (poor differentiation) in
five.
Immunoperoxidase staining
Frozen sections were cut at 5 ytm, air dried for 30 min and
fixed in cold acetone for 10 min. One section from each
sample was subjected to immunohistochemical staining for
EGFR and c-erbB-2 and to examination of histopathology.
The immunohistochemical study was performed using the
streptavidin-biotin bridge technique as described elsewhere
(Tomita et al., 1990). Briefly, after rehydration with
phosphate-buffered saline (PBS), the sections were incubated
in 20% normal sheep serum or 20% normal donkey serum
(Antibodies, Davis, CA, USA) in PBS for 30min.
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Endogenous biotin was blocked using the Endogenous Biotin
Blocking Kit (Vector Laboratories, Burlingame, CA, USA).
The sections then were incubated with mouse monoclonal
anti-human EGFR antibodies (Transformation Research,
Framingham. MA. USA) or rabbit polyclonal anti-human
c-erbB-2 antibodies (Nichireil Tokyo. Japan) for 60 min fol-
lowed by incubation with biotinylated sheep anti-mouse or
donkey anti-rabbit serum (Amersham International, Amer-
sham, Bucks, UK) containing 20% human type AB serum
(Biological Speciality, Lansdale. PA, USA). Subsequently,
they were incubated for 45 min with streptavidin peroxidase
(Amersham). Each step was followed by three washes in
PBS. Finally, the sections were immersed in 0.05%
diaminobenzidine (Sigma, St Louis, MO, USA) and 0.01%
hydrogen peroxide in 0.05 M Tris-HCI buffer for 3-5 min to
visualise the reaction products. After washing the sections in
tap water, they were counterstained in Mayer's haematoxylin
and mounted with Eukitt (O Kuldler, Freiburg, Germany)
after dehydration in graded ethanol and xylene solutions. For
determination of the optimal dilution of each antibody, A
431 cells (Ullnrch et al., 1984) for EGFR expression and
MKN7 cells (Yamamoto et al., 1986) for c-erbB-2 expression
were examined. For the evaluation of staining, the approx-
imate percentage of positive cells was estimated in randomly
selected fields at a magnification of x 100 under a micro-
scope equipped with a graticule. In ten examples of normal
transitional epithelium (two from renal pelvis, three from
ureter and five from urinary bladder) we could detect only
less than 25% positively cells (Kimura et al., 1992).
Therefore, when the percentage of positive TCCs exceeded
25%. the specimens were scored as exhibiting increased exp-
ression for each receptor protein.
Results
Thirteen of the 30 TCCs (43.3%) exhibited increased expres-
sion of the EGFR. and 11 TCCs (36.7%) showed increased
c-erbB-2 expression (Figure 1). Increased c-erbB-2 expression
was not associated with histological grade or tumour stage.
however increased EGFR expression was found more fre-
quently in patients having invasion of the deeper layer of the
renal pelvis or ureter (P<0.05. = 4.887. Yates' correction)
(Table I). All patients with stage pT3 cancers showed overex-
pression of the EGFR or c-erbB-2 proteins.
Secondary urinary bladder cancers occurred in 12 of the 30
patients (40.0%) after total nephroureterectomy. Although
higher grade and higher stage tumours tended to recur fre-
quently in the bladder, this difference was not statistically
significant in this study (Table II). Recurrence in the bladder
occurred in only one of the ten patients (10.0%), whose
tumour showed no increase in expression of either receptor.
On the other hand, in 11 of 20 (55.0%) patients with
tumours showing increased EGFR or c-erbB-2 expression, a
secondary urinary bladder cancer occurred after surgery, and
this difference was significant statistically (P<0.05, Fisher's
exact probability method) (Table III). The follow-up period
ranged from 116 to 2348 days (mean 666 days). The mean
period until a secondary urinary bladder cancer occurred was
306 days (116-829 days). The recurrence rate of TCCs show-
ing increased EGFR and or c-erbB-2 expression was signifi-
cantly higher than that of tumours showing no increased
expression of these receptor proteins (Kaplan-Meier
method, P<0.01. generalised Wilcoxon test) (Figure 2).
For patients suffering from renal pelvic cancer or ureteral
cancer, continued follow-up is required because of the pos-
sibility of recurrence in the urinary bladder after total neph-
roureterectomy. In several reports. the histopathological
grade of TCCs in the upper urinary tract was considered a
factor predictive of such recurrence (Murphy et al., 1981;
Figue 1 Grade 1. pTa. transitional cell cancer of the ureter
positively stained with both EGFR (a) and c-erbB-2 (b). Secon-
dary urinary bladder cancer occurred in the patient after total
nephroureterectomy. The interval until recurrence was 829 days.
Bar = 75 jim.
Table I Expression of epidermal grow-th factor receptor (EGFR)
and c-erbB-2 protein in relation to tumour grade and stage
Grade pT stage
1 2 3 I 2
EGFR (0)
)25 3 5 5 3 10 ] *
<25 2 15 0 12 5
c-erbB-2 (00)
25 3 7 1 7 4
<25 2 13 4 8 1 1
EGFR. epidermal grow-th factor receptor. *P<(0.05 (x = 4.887.
Yates' correction).
Table II Relationship between secondary bladder recurrence (12 of
30 patients) and tumour grade and stage
Grade pT stage
1 ' 3 a 1 2 3
Bladder recurrence
(+) 2 7 3 2 1 4 5
(-) 3 13 2 5 7 3 3
Krogh et al.. 1991). but data from other series of patients.
suggest that there is no relation between the recurrence rate
and grade or stage (Yoneda et al., 1989). It seems that the
classification of TCCs in the upper urinary tract by conven-
tional pathological criteria does not always help in the
prediction of bladder recurrence. Therefore. there is a need to
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Table IH Tumours grouped according to increased expression of
EGFR and or c-erbB-2 vs no increased expression of either in
relation to secondary bladder recurrence
Bladder recurrence
EGFR c-erbB-2
25% and or )25o 11 9 *
<25% and <25°/ 1 9
EGFR. epidermal growth factor receptor- *P<0.05 (Fisher's exact
probability method).
identify a characteristic of tumour cells associated with the
risk of recurrence in the bladder to enable identification of
patients with either a low recurrence rate (who do not need
follow-up) or a high recurrence rate (who might benefit from
more intensive treatment and frequent examination).
Clinical and urinary tract mapping studies suggest that
TCC is usually a field change disease with tumours arising at
different times and sites in the urothelium. This suggests the
possibility of a polyclonal aetiology of urothelial cancer.
However, it does not exclude the possibility that, in some
cases, multiple tumours are derived from a single-cell clone
that has disseminated to other sites in the urinary tract by
implantation. The determination of quantitative or
qualitative changes in the expression of oncogenes and their
protein products might be useful for classifying tumours into
different prognostic categories, since such changes at the
cellular level may lead directly to alterations in tumour
behaviour. Such information might well supplement tradit-
ional prognostic factors such as tumour grade and stage.
Increased expression of the epidermal growth factor receptor
(EGFR) and c-erbB-2 protein is found in urothelial cancers,
and has been reported to be associated with tumour
invasiveness, pathological malignancy, distant metastasis and
clinical prognosis (Neal et al., 1985, 1990; Moriyama et al.,
1991; Kimura et al., 1992; Lipponen and Eskelinen, 1994). In
this study, secondary unrnary bladder cancers occurred in 12
of 30 patients with renal pelvic TCC or ureteral TCC after
total nephroureterectomy. Eleven of the 20 patients (55.0%)
showing increased expression of EGFR and or c-erbB-2
100
u 80 EGFR <25% and c-erbB-2 <25% (n =10)
C
60 ,6- LI
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EGFR .25% and/or c-erbB-2 .25% (n =20) 20
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Post-operative days (x 103)
Fire 2 Rate of secondary bladder recurrence: tumour with
increased expression of EGFR and or c-erbB-2 (solid line) and
tumours with no increased expression of either (dotted line)
(Kaplan-Meier method. P<0.01. generalised Wilcoxon test).
developed a recurrence in the urinary bladder. In contrast
only one of the ten patients (10.0%) whose TCCs overex-
pressed neither EGFR nor c-erbB-2 exhibited a recurrence
(P<0.05). On the other hand. we could not find any signifi-
cant correlation between tumour grade or stage and inci-
dence of urinary bladder recurrence of tumour. Furthermore.
the mean period until recurrence in the urinary bladder was
306 days, and there was a significant difference in the recur-
rence rate in TCCs with increased EGFR or c-erbB-2 expres-
sion and the recurrence rate of TCCs with no increased
expression (P<0.01). These results suggest that the immuno-
histochemical detection of EGFR and c-erbB-2 in urothelial
cancers of the upper urinary tract might be a useful method
for determining the recurrence potential in the urinary
bladder.
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